Results 81 to 90 of about 24,853 (244)

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Haematologica, 2013
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian   +22 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review

Frontiers in Oncology
Myelofibrosis (MF) is a philadelphia chromosome-negative chronic myeloprolifera- tive neoplasm.It has a worse prognosis than polycythemia vera and essential thrombocy- themia.At present,both Chinese and foreign guidelines recommend ruxolitinib as first ...
Xiaohong Liu, Xiujuan Zhang, Hongxia Shi
doaj   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +5 more sources

Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study

Cancer
Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2‐high risk (INT2/HIGH) patients.
F. Palandri, E. Elli, E. Morsia, G. Benevolo, M. Tiribelli, E. Beggiato, M. Bonifacio, M. Farina, B. Martino, G. Caocci, N. Pugliese, A. Tieghi, M. Crugnola, G. Binotto, F. Cavazzini, E. Abruzzese, A. Iurlo, A. Isidori, C. Bosi, Veronica Guglielmana, M. Venturi, A. Dedola, M. Loffredo, G. Fontana, A. Duminuco, A. Moioli, Luca Tosoni, E. Scalzulli, D. Cattaneo, R. Lemoli, D. Cilloni, M. Bocchia, F. Pane, F. Heidel, N. Vianelli, M. Cavo, G. Palumbo, F. Branzanti, M. Breccia   +38 more
semanticscholar   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT

Blood Advances
Key Points • Ruxolitinib therapy was associated with improvements in lung function for participants with BOS.• Clinical responses were more commonly observed in participants with mild or moderate BOS.
Zachariah M DeFilipp, Haesook T. Kim, Guang-Shing Cheng, Betty K. Hamilton, S. Chhabra, M. Hamadani, Karamjeet S. Sandhu, Lia E Perez, Catherine J. Lee, Timothy L Brennan, Cassandra Garrelts, Bergin M Brown, Kathleen Gallagher, Richard A. Newcomb, A. El-Jawahri, Yi-Bin Chen   +15 more
semanticscholar   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source